The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation

The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation

Aim. To compare the change in quality of life indicators and the main clinical and instrumental parameters in patients with chronic heart failure (CHF) and functional mitral regurgitation (FMR) under the influence of sacubitril/valsartan compared with valsartan in an outpatient practice.Material and...

Full description

Bibliographic Details
Main Authors:	A. S. Ryazanov, E. V. Shikh, O. V. Kechina, M. V. Makarovskaya, A. A. Kudryavtsev
Format:	Article
Language:	English
Published:	Столичная издательская компания 2023-01-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	heart failure quality of life neprilysin angiotensin receptor blockers
Online Access:	https://www.rpcardio.online/jour/article/view/2853

Similar Items

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling
by: A.S. Ryazanov, et al.
Published: (2023-04-01)

Long-Term Effects of Angiotensin Receptor–Neprilysin Inhibitors on Myocardial Function in Chronic Heart Failure Patients with Reduced Ejection Fraction
by: Gregor Poglajen, et al.
Published: (2020-07-01)

Outcome of angiotensin receptor-neprilysin inhibitor on anxiety and depression in heart failure with reduced ejection fraction vs. heart failure with preserved ejection fraction
by: Jahanzeb Malik, et al.
Published: (2021-09-01)

Impact of the angiotensin receptor‐neprilysin inhibitor in clinical diabetes management: Potential benefits and pitfalls
by: Tomoko Kato, et al.
Published: (2023-09-01)

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
by: Hong-Mi Choi, et al.
Published: (2020-05-01)

Use of angiotensin receptor – neprilysin inhibitors in heart failure: a paradigm shift
by: M. O.E. Irhuma, et al.
Published: (2016-11-01)

Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction
by: Su Yeong Park, et al.
Published: (2023-09-01)

Safety and effectiveness of angiotensin receptor-neprilysin inhibitors in Indian patients with heart failure with preserved ejection fraction – “ARNI-PRESERVED” study
by: Pankaj Jariwala, et al.
Published: (2021-01-01)

Effect of Neprilysin Inhibition for Ischemic Mitral Regurgitation after Myocardial Injury
by: Sahmin Lee, et al.
Published: (2021-08-01)

Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
by: Kawa Dizaye, et al.
Published: (2019-05-01)

Anti-hypertensive effect of a novel angiotensin II receptor neprilysin inhibitor (ARNi) -S086 in DSS rat model
by: Jingchao Sun, et al.
Published: (2024-02-01)

Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP‐HF
by: Brittany Chapman, et al.
Published: (2022-06-01)

Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias
by: Henry Sutanto, et al.
Published: (2021-08-01)

Angiotensin receptor-neprilysin inhibitor in patients with heart failure and chronic kidney disease
by: In-Jeong Cho, et al.
Published: (2021-12-01)

Getting the “Right” Perspective on Angiotensin Receptor–Neprilysin Inhibition in Heart Failure
by: Frederik H. Verbrugge, et al.
Published: (2020-07-01)

A clinical experience of Indian patients with heart failure with reduced left ventricular ejection fraction using an angiotensin receptor-neprilysin inhibitor [ARNI] on an outpatient basis
by: Pankaj Jariwala, et al.
Published: (2021-03-01)

B-Type Natriuretic Peptide (BNP) Revisited—Is BNP Still a Biomarker for Heart Failure in the Angiotensin Receptor/Neprilysin Inhibitor Era?
by: Toshio Nishikimi, et al.
Published: (2022-07-01)

Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series
by: Sepideh Taghavi, et al.
Published: (2020-12-01)

Angiotensin receptor neprilysin inhibitor in heart failure with reduced ejection fraction: Real-world experience from a safety perspective
by: Manas Layek, et al.
Published: (2020-01-01)

Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction
by: Akihiro Nakamura, et al.
Published: (2023-01-01)

Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats
by: Shao-Jung Hsu, et al.
Published: (2020-04-01)

Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe
by: Donna S.‐H. Lin, et al.
Published: (2021-03-01)

Angiotensin receptor‐neprilysin inhibitor in symptomatic patients with Duchenne dilated cardiomyopathy: A primetime
by: Alessandra Arcudi, et al.
Published: (2022-10-01)

Reply to Siniorakis et al., “COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure”
by: David S. Fedson, et al.
Published: (2020-06-01)

Insulinotropic Effects of Neprilysin and/or Angiotensin Receptor Inhibition in Mice
by: Nathalie Esser, et al.
Published: (2022-06-01)

Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor
by: Teng Y, et al.
Published: (2023-08-01)

The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19
by: Alessandro Bellis, et al.
Published: (2020-11-01)

Influence of angiotensin receptor-neprilysin inhibition on the efficacy of Empagliflozin on cardiac structure and function in patients with chronic heart failure and a reduced ejection fraction: The Empire HF trial
by: Julie Hempel Larsen, et al.
Published: (2023-02-01)

Effects of angiotensin receptor‐neprilysin inhibitor on insulin resistance in patients with heart failure
by: Yusuke Kashiwagi, et al.
Published: (2023-06-01)

Neprilysin Inhibitors and Bradykinin
by: Duncan J. Campbell, et al.
Published: (2018-09-01)

Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis
by: Wipharak Rattanavipanon, et al.
Published: (2021-07-01)

Initiation, treatment response evaluation, and safety monitoring of angiotensin receptor/neprilysin inhibitors (Sacubitril/Valsartan) in the management of heart failure in India: An expert group recommendations
by: Uday M Jadhav, et al.
Published: (2023-01-01)

Angiotensin receptor-neprilysin inhibitor improves coronary collateral perfusion
by: Kangbo Li, et al.
Published: (2023-02-01)

Angiotensin Receptor Antagonist-Neprilysin Inhibitor (ARNI) therapy as a new hope in the population of people with heart failure with reduced ejection fraction (HFrEF)
by: Przemysław Żelazny, et al.
Published: (2022-09-01)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
by: Sarah L Anderson, et al.
Published: (2018-08-01)

Sacubitril/Valsartan Initiation Among Veterans Who Are Renin‐Angiotensin‐Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction
by: April F. Mohanty, et al.
Published: (2021-10-01)

Association Between Copayment Amount and Filling of Medications for Angiotensin Receptor Neprilysin Inhibitors in Patients With Heart Failure
by: Amrita Mukhopadhyay, et al.
Published: (2022-12-01)

Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension
by: Wanjing Li, et al.
Published: (2022-04-01)

Neurohumoral Activation in Heart Failure
by: Antonis A. Manolis, et al.
Published: (2023-10-01)

Application of Angiotensin Receptor–Neprilysin Inhibitor in Chronic Kidney Disease Patients: Chinese Expert Consensus
by: Liangying Gan, et al.
Published: (2022-07-01)